GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Inventories, Raw Materials & Components

CERO (CERo Therapeutics Holdings) Inventories, Raw Materials & Components : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Inventories, Raw Materials & Components?

CERo Therapeutics Holdings's inventories, raw materials & components for the quarter that ended in Mar. 2025 was $0.00 Mil.


CERo Therapeutics Holdings Inventories, Raw Materials & Components Historical Data

The historical data trend for CERo Therapeutics Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Inventories, Raw Materials & Components Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
- - - -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CERo Therapeutics Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


CERo Therapeutics Holdings Business Description

Industry
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

CERo Therapeutics Holdings Headlines

From GuruFocus